Statistics

Total Visits

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer29

Select a period of time:

Number of views in the range

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer16

Views

Views
October 20240
November 20241
December 20240
January 20251
February 20251
March 202513
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore13
United States2
Canada1
 

Top cities views

Views
Buffalo1
Toronto1